Publicaciones (55) Publicaciones de María Jesús Garrido Cid

2023

  1. Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling

    Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632

2022

  1. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 3

  2. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

    Science Translational Medicine, Vol. 14, Núm. 627

  3. Stealth nanoparticles in oncology: Facing the PEG dilemma

    Journal of Controlled Release, Vol. 351, pp. 22-36

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration

    Frontiers in Pharmacology, Vol. 12

  3. Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

    British Journal of Cancer, Vol. 124, Núm. 7, pp. 1275-1285

  4. Semi-mechanistic model for the antitumor response of a combination cocktail of immuno-modulators in non-inflamed (Cold) tumors

    Cancers, Vol. 13, Núm. 20

2020

  1. Drug Exposure to Establish Pharmacokinetic–Response Relationships in Oncology

    Clinical Pharmacokinetics, Vol. 59, Núm. 2, pp. 123-135

  2. Modificaciones farmacocinéticas y farmacodinámicas en el anciano

    Tratado de medicina geriátrica: fundamentos de la atención sanitaria a los mayores (Elsevier), pp. 72-82

  3. Quantification of pharmacokinetic profiles of pd-1/pd-l1 antibodies by validated elisas

    Pharmaceutics, Vol. 12, Núm. 6, pp. 1-16

2019

  1. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  2. Optimization and in-vitro/in-vivo evaluation of doxorubicin-loaded chitosan-alginate nanoparticles using a melanoma mouse model

    International Journal of Pharmaceutics, Vol. 556, pp. 1-8

  3. Pharmacokinetic and pharmacodynamic modelling in anaesthesia

    Personalized Anaesthesia: Targeting Physiological Systems for Optimal Effect (Cambridge University Press), pp. 14-28

2018

  1. Immunoliposomes in clinical oncology: State of the art and future perspectives

    Journal of Controlled Release, Vol. 275, pp. 162-176

2017

  1. Commentary on Pharmacometrics for Immunotherapy

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, Núm. 1, pp. 8-10

  2. Comparison of liposomal drug formulations for transdermal iontophoretic drug delivery

    European Journal of Pharmaceutical Sciences, Vol. 106, pp. 294-301

  3. Population pharmacokinetics of clarithromycin in Mexican hospitalized patients with respiratory disease: Evidence for a reduced clearance

    International Journal of Pharmacology, Vol. 13, Núm. 1, pp. 54-63

2016

  1. Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model

    Oncotarget, Vol. 7, Núm. 47, pp. 76891-76901

  2. EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model

    Nanomedicine, Vol. 11, Núm. 5, pp. 465-477